Gallstones - Approach to medical management

MedGenMed Medscape General Medicine

Volumn 5, Issue 4, 2003, Pages

  Konikoff, Fred M ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTICHOLELITHIASIS AGENT; BETA MUCRICHOLIC ACID; BILE ACID CONJUGATE; CHENODEOXYCHOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TERPENE DERIVATIVE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

BILE DUCT INJURY; CHOLANGIOGRAPHY; CHOLECYSTECTOMY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIARRHEA; DISEASE RESISTANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACORPOREAL LITHOTRIPSY; GALLSTONE; GALLSTONE DISSOLUTION; GALLSTONE FORMATION; HUMAN; LIVER TOXICITY; META ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT INDICATION;

EID: 25144518617     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Konikoff FM, Donovan JM. Gallstone disease: pathogenesis and treatment. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins; 2002:651-672.
2. Lam CM, Murray FE, Cuschieri A. Increased cholecystectomy rate after the introduction of laparoscopic cholecystectomy in Scotland. Gut. 1996;38:282-284.
3. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-1511.
4. Deziel DJ, Millikan KW, Economou SG, Doolas A, Ko ST, Airan MC. Complications of laparoscopic cholecystectomy - A national survey of 4,292 hospitals and an analysis of 77,604 cases. Am J Surg. 1993;165: 9-14.
5. Deziel DJ. Complications of cholecystectomy - Incidence, clinical manifestations, and diagnosis. Surg Clin North Am. 1994;74: 809-823.
6. Francoeur JR, Wiseman K, Buczkowski AK, Chung SW, Scudamore CH. Surgeons' anonymous response after bile duct injury during cholecystectomy. Am J Surg. 2003;185:468-475.
7. Shea JA, Healey MJ, Berlin JA, et al. Mortality and complications associated with laparoscopic cholecystectomy: A meta-analysis. Ann Surg. 1996;224:609-620.
8. Heinrich S, Seifert H, Krahenbuhl L, Fellbaum C, Lorenz M. Right hemihepatectomy for bile duct injury following laparoscopic cholecystectomy. Surg Endosc. 2003;Jun 25. Epub ahead of print.
9. Nordin A, Halme L, Makisalo H, Isoniemi H, Hockerstedt K. Management and outcome of major bile duct injuries after laparoscopic cholecystectomy: from therapeutic endoscopy to liver transplantation. Liver Transpl. 2002;8:1036-1043.
10. Giovannucci E, Colditz GA, Stampfer MJ. A meta-analysis of cholecystectomy and risk of colorectal cancer. Gastroenterology. 1993;105:130-141.
11. Schernhammer, ES, Leitzmann MF, Michaud D et al. Cholecystectomy and the risk for developing colorectal cancer and distal colorectal adenomas. Brit J Cancer. 2003;88:79-83.
12. Ros E, Zambon D. Postcholecystectomy symptoms. A prospective study of gall stone patients before and two years after surgery. Gut. 1987;28:1500-1504.
13. Vander Velpen GC, Shimi SM, Cuschieri A. Outcome After Cholecystectomy for symptomatic gall stone disease and effect of surgical access - laparoscopic vs open approach. Gut. 1993;34:1448-1451.
14. Ransohoff DF, Gracie WA. Management of patients with symptomatic gallstones: A quantitative analysis. Am J Med. 1990;88:154-160.
15. Vetrhus M, Soreide O, Solhaug JH, Nesvik I, Sondenaa K. Symptomatic, non-complicated gallbladder stone disease. Operation or observation? A randomized clinical study. Scand J Gastroenterol. 2002;37:834-839.
16. Jorgensen, T. Treatment of patients with uncomplicated gallbladder stones? Scand J Gastroenterol. 2002;37:745.
17. Abe A, Tsuchiya Y, Sugiura N, Saisho H, Nishimura K, Takeo K. Ultrastructure of cholesterol gallstones as observed by electron microscopy after freeze-fracturing. Tissue Cell. 1997;29:191-197.
18. Carey MC. Formation and growth of cholesterol gallstones: the new synthesis. In: Fromm H, Leuschner U, eds. Bile Acids - Cholestasis - Gallstones. Advances in Basic and Clinical Bile Acid Research. Dordrecht, Holland: Kluwer Academic Publishers; 1996:147-175.
19. Donovan JM, Carey MC. Physical-chemical basis of gallstone formation. Gastroenterol Clin North Am. 1991;20:47-66.
20. Gilat T, Somjen GJ. Phospholipid vesicles and other cholesterol carriers in bile. Biochim Biophys Acta. 1996;1286:95-115.
21. Konikoff FM, Donovan JM. Cholesterol crystallization in bile. In: Afdhal NH, ed. Gallbladder and Biliary Tract Diseases. New York: Marcel Dekker, Inc.; 2000:185-209.
22. Rewbridge AG. The disappearance of gallstone shadows following the prolonged administration of bile salts. Surgery. 1937;1:395-400.
23. Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med. 1972;286:1-8.
24. Bell GD, Whitney B, Dowling RH. Gallstone dissolution in man using chenodeoxycholic acid. Lancet. 1972;2:1213-1216.
25. Nakagawa S, Makino I, Ishizaki T. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet. 1977;2:367-369.
26. Schoenfield LJ, Lachin JM. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann Intern Med. 1981;95:257-282.
27. Fromm H, Roat JW, Gonzales V, Sarva RP, Farivar S. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. Gastroenterology. 1983;85:1257-1264.
28. Paumgartner G, Pauletzki J, Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol. 1994;29:27-31.
29. Stiehl A, Czygan P, Kommerell B, Weis HJ, Holtermuller KH. Ursodeoxycholic acid versus chenodeoxycholic acid. Comparison of their effects on bile acid and bile lipid composition in patients with cholesterol gallstones. Gastroenterology. 1978;75:1016-1020.
30. Salen G, Tint GS, Shefer S. Oral dissolution treatment of gallstones with bile acids. Semin Liver Dis. 1990;10:181-190.
31. Su CC, Park JY, Higuchi WI, et al. Mesophase formation during In Vitro cholesterol gallstone dissolution: a specific effect of ursodeoxycholic acid. J Pharm Sci. 1981;70:713-715.
32. Park Y-H, Igimi H, Carey MC. Dissolution of human cholesterol gallstones in simulated chenodeoxycholate-rich and ursodeoxycholate-rich biles. An in vitro study of dissolution rates and mechanisms. Gastroenterology. 1984;87:150-158.
33. Petroni ML, Jazrawi RP, Pazzi P, et al. Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. Aliment Pharmacol Therapeut. 2001;15:123-128.
34. Podda M, Zuin M, Dioguardi ML, Festorazzi S, Dioguardi N. A combination of chenodeoxycholic acid and ursodeoxycholic acid is more effective than either alone in reducing biliary cholesterol saturation. Hepatology. 1982;2:334-339.
35. Kupfer RM, Maudgal DP, Northfield TC. Gallstone dissolution rate during chenic acid therapy. Effect of bedtime administration plus low cholesterol diet. Dig Dis Sci. 1982;27:1025-1029.
36. Lanzini A, Facchinetti D, Northfield TC. Maintenance of hepatic bile acid secretion rate during overnight fasting by bedtime bile acid administration. Gastroenterology. 1988;95:1029-1035.
37. Senior JR, Johnson MF, DeTurck DM, Bazzoli F, Roda E. In vivo kinetics of radiolucent gallstone dissolution by oral dihydroxy bile acids. Gastroenterology. 1990;99:243-251.
38. Bateson MC, Bouchier IA, Trash DB, Maudgal DP, Northfield TC. Calcification of radiolucent gall stone during treatment with ursodeoxycholic acid. Br Med J (Clin Res Ed). 1981;283:645-646.
39. Neligan P, Bateson MC, Trash DB, Ross PE, Bouchier IA. Ursodeoxycholic acid for the dissolution of radiolucent gall bladder stones. Digestion. 1983;28:225-233.
40. Maglinte DD, Torres WE, Laufer I. Oral cholecystography in contemporary gallstone imaging: a review. Radiology. 1991;178:49-58.
41. Malet PF, Baker J, Kahn MJ, Soloway RD. Gallstone composition in relation to buoyancy at oral cholecystography. Radiology. 1990;177:167-169.
42. Muraca M, Cianci V, Vilei MT, Burighel D. Ultrasonic evaluation of gallbladder emptying with ceruletide. Ital J Gastroenterol. 1996;28:38-39.
43. Bellamy PR, Hicks A. Assessment of gallbladder function by ultrasound: implications for dissolution therapy. Clin Radiol. 1988;39:511-512.
44. Krishnamurthy GT, Brown PH. Comparison of fatty meal and intravenous cholecystokinin infusion for gallbladder ejection fraction. J Nucl Med. 2002;43:1603-1610.
45. Kapoor BS, Agarwal AK, Khanna NN. Prediction of gall stone composition by ultrasound: Implications for non-surgical therapy. Br J Radiol. 1995;68:459-462.
46. Tsuchiya Y, Saito H, Saito N, et al. Sonographic patterns of radiolucent gall-bladder stones for predicting successful shock-wave lithotripsy. J Gastroenterol Hepatol. 1995;10:426-431.
47. Rambow A, Staritz M, Wosiewitz U, Mildenburger P, Thelen M, Meyer zum Buschenfelde KH. Analysis of radiolucent gallstones by computed tomography for in vivo estimation of stone components. Eur J Clin Invest. 1990;20:475-478.
48. Walters JRF, Hood KA, Gleeson D, et al. Combination therapy with oral ursodeoxycholic and chenodeoxycholic acids: pretreatment computed tomography of the gall bladder improves gall stone dissolution efficacy. Gut. 1992;33:375-380.
49. Petroni ML, Jazrawi RP, Grundy A, et al. Prospective, multicenter study on value of computerized tomography (CT) in gallstone disease in predicting response to bile acid therapy. Dig Dis Sci. 1995;40:1956-1962.
50. Gleeson D, Ruppin DC. Discrepancies between cholecystography and ultrasonography in the detection of recurrent gallstones. J Hepatol. 1985;1:597-607.
51. May GR, Sutherland LR, Shaffer EA. Efficacy of bile acid therapy for gallstone dissolution - a meta-analysis of randomized trials. Aliment Pharmacol Therapeut. 1993;7:139-148.
52. Strasberg SM, Clavien P-A. Cholecystolithiasis: lithotherapy for the 1990s. Hepatology. 1992;16:820-839.
53. Jazrawi RP, Pigozzi MG, Galatola G, Lanzini A, Northfield TC. Optimum bile acid treatment for rapid gall stone dissolution. Gut. 1992;33:381-386.
54. Sauerbruch T, Delius M, Paumgartner G, et al. Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med. 1986;314:818-822.
55. Sackmann M, Pauletzki J, Sauerbruch T, Holl J, Schelling G, Paumgartner G. The Munich Gallbladder Lithotripsy Study. Results of the first 5 years with 711 patients. Ann Intern Med. 1991;114:290-296.
56. Mulagha E, Fromm H. Extracorporeal shock wave lithotripsy of gallstones revisited: current status and future promises. J Gastroenterol Hepatol. 2000;15:239-243.
57. Bentzen E, Boesby S, Faarvang HJ, et al. Bile acid therapy versus placebo before and after extracorporeal shock wave lithotripsy of gallbladder stones. Aliment Pharmacol Therapeut. 1996;10:651-657.
58. Nicholl JP, Ross B, Milner PC, et al. Cost effectiveness of adjuvant bile salt treatment in extracorporeal shock wave lithotripsy for the treatment of gall bladder stones. Gut. 1994;35:1294-1300.
59. Lanzini A, Jazrawi RP, Kupfer RM, Maudgal DP, Joseph AE, Northfield TC. Gallstone recurrence after medical dissolution. An overestimated threat? J Hepatol. 1986;3:241-246.
60. Petroni ML, Jazrawi RP, Pazzi P, et al. Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol. 2000;12:695-700.
61. Petroni ML, Jazrawi RP, Lanzini A, et al. Repeated bile acid therapy for the long-term management of cholesterol gallstones. J Hepatol. 1996;25:719-724.
62. Pereira SP, Hussaini SH, Kennedy C, Dowling RH. Gallbladder stone recurrence after medical treatment: Do gallstones recur true to type? Dig Dis Sci.1995;40:2568-2575.
63. Villanova N, Bazzoli F, Taroni F, et al. Gallstone recurrence after successful oral bile acid treatment. A 12-year follow-up study and evaluation of long-term postdissolution treatment. Gastroenterology. 1989;97:726-731.
64. Sackmann M, Niller H, Klueppelberg U, et al: Gallstone recurrence after shock-wave therapy. Gastroenterology. 1994;106:225-230.
65. Pauletzki J, Althaus R, Holl J, Sackmann M, Paumgartner G. Gallbladder emptying and gallstone formation: A prospective study on gallstone recurrence. Gastroenterology. 1996;111:765-771.
66. Berr F, Mayer M, Sackmann MF, Sauerbruch T, Holl J, Paumgartner G. Pathogenic factors in early recurrence of cholesterol gallstones. Gastroenterology. 1994;106:215-224.
67. Portincasa P, van Erpecum KJ, van de Meeberg P, Dallingathie GM, Debruin TWA, van Berge-Henegouwen GP. Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy. Hepatology. 1996;24:580-587.
68. O'Leary DP, Johnson AG. Future directions for conservative treatment of gallbladder calculi. Br.J.Surg. 1993;80:143-147.
69. Gilat T, Konikoff FM. Pregnancy and the biliary tract. Can J Gastroenterol. 2000;14:55-59.
70. Testoni PA, Caporuscio S, Bagnolo F, Lella F. Idiopathic recurrent pancreatitis: long-term results after ERCP, endoscopic sphincterotomy, or ursodeoxycholic acid treatment. Am J Gastroenterol. 2000;95:1702-1707.
71. Ros E. Microcrystalline components of bile can predict gallstone (GS) composition and the outcome of dissolution therapy with ursodeoxycholic acid (UDCA). In: Barbara L, Dowling H, eds. Recent Advances in Bile Acid Research. New York: Raven Press; 1985:163-164.
72. Ros E, Navarro S, Bru C, Garcia-Puges A, Valderrama R. Occult microlithiasis in 'idiopathic' acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic acid therapy. Gastroenterology. 1991;101:1701-1709.
73. Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000;12:1347-1352.
74. Shiffman ML, Sugerman HJ, Kellum JM, Brewer WH, Moore EW. Gallstone formation after rapid weight loss: A prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol. 1991;86:1000-1005.
75. Fobi M, Lee H, Igwe D, et al. Prophylactic cholecystectomy with gastric bypass operation: incidence of gallbladder disease. Obes Surg. 2002;12:350-353.
76. Shiffman ML, Kaplan GD, Brinkmankaplan V, Vickers FF. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very- low-calorie diet program. Ann Intern Med. 1995;122:899-905.
77. Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double- blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass- induced rapid weight loss. Am J Surg. 1995;169:91-97.
78. Tomida S, Abei M, Yamaguchi T, et al. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: A cohort analysis. Hepatology. 1999;30:6-13.
79. Diehl AK, Holleman DR, Chapman JB, Schwesinger WH, Kurtin WE. Gallstone size and risk of pancreatitis. Arch Intern Med. 1997;157:1674-1678.
80. Simoni P, Cerre C, Cipolla A, et al. Bioavailability study of a new, sinking, enteric-coated ursodeoxycholic acid formulation. Pharmacol Res. 1995;31:115-119.
81. Muraca M, Vilei MT, Cianci V, Liu XT, Garotta F. Effect of tauroursodeoxycholic acid on biliary lipid composition. A dose-response study. Int J Clin Pharm Ther. 1995;33:391-393.
82. Wang DQH, Tazuma S. Effect of beta-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. J Lipid Res. 2002;43:1960-1968.
83. Abedin MZ, Narins SC, Park EH, Smith PR, Kirkwood KS. Lovastatin alters biliary lipid composition and dissolves gallstones - A long-term study in prairie dogs. Dig Dis Sci. 2002;47:2192-2210.
84. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology. 1988;8:1147-1150.
85. Logan GM, Duane WC. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology. 1990;98:1572-1576.
86. Sackmann M, Koelbl R, Pauletzki J, et al. Simvastatin added to ursodeoxycholic acid does not enhance disappearance of gallstone fragments after shock wave therapy. Z Gastroenterol. 1995;33:585-589.
87. Tazuma S, Kajiyama G, Mizuno T, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol. 1998;26:287-291.
88. Chapman BA, Burt MJ, Chisholm RJ, Allan RB, Yeo KHJ, Ross AG. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci. 1998;43:349-353.
89. Hillebrant CG, Nyberg B, Gustafsson U, et al. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism. Eur J Clin Invest. 2002;32:528-534.
90. Bell GD. Medical treatment of gallstones. J R Coll Physicians Lond. 1979;13:47-52.
91. Handelsman B, Bonorris G, Marks JW, Schoenfield LJ. Rowachol and ursodeoxycholic acid in hamsters with cholesterol gallstones. Am J Med Sci. 1982;284:16-22.
92. Leiss O, von Bergmann K. Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers. Gut. 1985;26:32-37.
93. von Bergmann K, Beck A, Engel C, Leiss O. Administration of a terpene mixture inhibits cholesterol nucleation in bile from patients with cholesterol gallstones. Klin Wochenschr. 1987;65:458-462.
94. Leuschner M, Leuschner U, Lazarovici D, Kurtz W, Hellstern A. Dissolution of gall stones with an ursodeoxycholic acid menthol preparation: a controlled prospective double blind trial. Gut. 1988;29:428-432.
95. Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7 alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002;110:109-117.
96. Jungst D, Lang T, Huber P, Lange V, Paumgartner G. Effect of phospholipids and bile acids on cholesterol nucleation time and vesicular/micellar cholesterol in gallbladder bile of patients with cholesterol stones. J Lipid Res. 1993;34:1457-1464.
97. Konikoff FM, Gilat T. The role of phospholipids in biliary cholesterol solubilization and precipitation. In: Recent Research Developments in Lipids. Vol 2. Kerala, India: Transworld Research Network: 1998:111-117.
98. Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology. 2001;120:1459-1467.
99. Gilat T, Somjen G J, Mazur Y, et al. Fatty acid bile acid conjugates (FABACs) - New molecules for the prevention of cholesterol crystallisation in bile. Gut. 2001;48:75-79.
100. Gilat T, Leikin-Frenkel A, Goldiner I, Laufer H, Halpern Z, Konikoff FM. Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice. Lipids. 2001;36:1135-1140.
101. Gilat T, Leikin-Frenkel A, Goldiner I, Halpern Z, Konikoff FM. Dissolution of cholesterol gallstones in mice by the oral administration of a fatty acid bile acid conjugate. Hepatology. 2002;35:597-600.